With slow vaccine distribution and manufacturing, some people won’t get the second dose on time. But does it matter?
Academic rigour, journalistic flair
Articles on mRNA
Displaying 41 - 51 of 51 articles
A biologist explains what proteins do in viruses, how they interact with human cells, how the vaccine delivers mRNA into the cell and how antibodies protect us.
Two pharmacists involved in COVID-19 vaccine preparation explain the role pharmacists are poised to play in expanding vaccine access.
Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Pfizer and BioNTech have announced 95% efficacy for their mRNA vaccine, having met the final target they need to before seeking regulatory approval.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
Two more COVID-19 vaccines may now be on the cards for Australia, should they pass clinical trials. But, as with earlier vaccine deals, there are no guarantees.
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.
Traditional vaccines can take years to create. Rather than immunizing people with viral proteins, the new approach gives the molecular instructions that allows the body to make its own vaccine.
Top contributors
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Medicine, University of Virginia
-
Postdoctoral Research Fellow, RNA Biology and Biochemistry, Brighton and Sussex Medical School
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Clinical Associate Professor of Pharmacy Practice, Binghamton University, State University of New York
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Professor and Department Chair of Infectious Diseases and Microbiology, University of Pittsburgh
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of virology and theme leader for viral infectious diseases, The Peter Doherty Institute for Infection and Immunity
-
Senior Lecturer; MD, Victoria University
-
Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco
